The announcement comes as skyrocketing demand for GLP-1 medications, the class of drugs that Ozempic, Wegovy and Eli Lillys Zepbound belong to, has made them harder to access
2 This is explained in part by the fact that there is often a delay in diagnosis due to uncharacteristic morphologies
This comparison examines mechanisms, efficacy data, side effects, approval timelines, and which medication will dominate when both reach market
Juan, S
Fiorentino TV, Monroy A, Kamath S, et al
Families also bear the ongoing expense and coordination of: Dexcom G6 sensor covers to protect highly sensitive skin Tandem Diabetes Care insulin pump patches to prevent allergic reactions Constant pharmacy visits for essential supplies